RIVANNA Receives $2.9M NIH Grant to Expand Accuro 3S Applications

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they received a $2.9 million grant from the National Institutes of Health (NIH). The grant will further the development of Accuro® 3S, designed for image-guided regional anesthesia, to broaden access to opioid-sparing analgesia for hip fracture pain.

Each year, over 330,000 Americans face hospitalization due to hip fractures, requiring immediate pain management and surgery for mobility restoration and mortality risk reduction. Conventional treatment involves parenteral opioids, which increase adverse events, including recurrent opioid use. Ultrasound-guided regional anesthesia (UGRA), like the pericapsular nerve group (PENG) block, provides an effective opioid-free alternative for 300,000 patients annually. However, barriers to UGRA adoption persist due to provider experience and specialized training limitations.

Accuro 3S represents a technological advancement designed to address UGRA barriers by equipping healthcare providers with workflow intelligence for hip regional anesthesia; this will effectively reduce training requirements, streamline workflow and enhance the utilization of hip regional anesthesia for hip fracture pain. Notable innovations within the Accuro 3S system include AI-based reconstructions of hip anatomy, real-time needle guidance with automated identification of essential anatomical landmarks and a novel ultrasound probe.

“Considering that more than one million PENG blocks are performed annually across 5,000 U.S. emergency departments, there is a pressing need to expand opioid-sparing UGRA for hip fracture pain, enhancing accessibility to safer medical procedures and improving patient outcomes,” commented Will Mauldin, PhD, co-founder and CEO of RIVANNA. “Our technology is well-positioned to bridge a crucial gap in healthcare delivery and expand the range of Accuro 3S clinical applications, unlocking a significant U.S. market opportunity estimated at $295 million annually.”

This funding opportunity is part of the NIH HEAL (Helping to End Addiction Long-term) Initiative and is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases under Award Number R44AR083337.

Recent News


ATCC Announces Award from NIAID to Consolidate its BEI Resources and NIH HIV Reagent Programs

ATCC, the world’s premier biological materials management and standards organization, today announced a seven-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to continue the management of the BEI Resources Program. NIAID has made an initial award of over $21.5 million, with further funding


Acclinate Collaborates with Merck to Increase Clinical Trial Diversity

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck’s oncology clinical studies. “We’re proud to be working with Merck because being a champion for health equity through inclusive research


cultivate(MD) Capital Funds LP Announces Investment into Nanochon

cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today that they have made a significant investment into Nanochon, a Washington, D.C.—based regenerative cartilage innovator. Nanochon develops solutions utilized by sports medicine physicians to treat active patients requiring cartilage restoration.  Nanochon’s Chondrograft™ replaces lost or damaged